Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Werewolf Therapeutics, Inc.

NASDAQ: HOWL · Life Sciences · 2 alerts · CIK 1785530

Share price
$0.9908Close, Nov 16
Market cap
$48.2M
Shares outstanding
48.6MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Werewolf Therapeutics, Inc. filings on SEC EDGAR ↗

4:09 PM ET 10-Q
Financial Results

Werewolf Therapeutics Q3 2026 Results: Net Loss of $9.88M, Loss Narrows

Werewolf Therapeutics is currently pursuing a merger with Ambros and a concurrent PIPE financing to address substantial doubt about its ability to continue as a going concern. As of November 9, 2026, the company had 48,599,066 shares of common stock outstanding and is evaluating strategies to raise additional capital to fund its research and development programs.

Key figure
Net loss $9.88M
9:23 AM ET 8-K
Clinical Trial Data

Werewolf Therapeutics Clinical Trial Data

Werewolf Therapeutics announced new clinical data from its Phase 1/1b trial of WTX-124 and Phase 1b/2 trial of WTX-330 for the treatment of solid tumors at the SITC 2026 Annual Meeting. WTX-124 demonstrated durable antitumor activity, including a complete response in a patient with cutaneous squamous cell carcinoma, and the company aligned with the FDA on a recommended Phase 2 dose of 18 mg. WTX-330 was reported as well-tolerated with evidence of monotherapy clinical activity in advanced, treatment-refractory disease.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.